Nevro Spine-Stim Patents Escape Re-Review By PTO
This article was originally published in The Gray Sheet
The Patent Trial and Appeals Board won’t review a Nevro spinal cord stimulator patent after a challenge from Boston Scientific claimed the patent was invalid because it was too similar to prior knowledge in the field. The unusual decision not to even launch a so-called inter partes review in this case should be comforting to device patent holders, an attorney says.
You may also be interested in...
The company says the Senza high-frequency system is the first spinal cord stimulator to be approved to claim superiority over existing spinal cord stimulation therapies. Approval is based on results of the highly touted SENZA-RCT trial.
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.
The US Food and Drug Administration posted two device-related closeout letters in November.